Who Paid My Doc
A Phase 3A, Observer-Blind, Randomized, Controlled Study to Evaluate T
Research payments
$1,360,442
Through program year 2025, $1,360,442 in research payments was reported against A Phase 3A, Observer-Blind, Randomized, Controlled Study to Evaluate T, across 198 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $1,360,442 | 198 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Michael Bornstein Richmond, TX Named on 23 payments
- Holly Lim West Covina, CA Named on 20 payments
- John Scott Richmond, VA Named on 13 payments
- Mary Smentek Mankato, MN Named on 13 payments
- Giselle Deiros Miami, FL Named on 13 payments
- Luke Anschutz Lincoln, NE Named on 13 payments
- Kashif Ali Houston, TX Named on 13 payments
- Ronald Blair Frisco, TX Named on 12 payments
- Chris Peltier Cincinnati, OH Named on 10 payments
- Peter Silas Syracuse, UT Named on 10 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.